Innoregen
Develops bioinks and hydrogels for 3D bioprinting of artificial organs and regenerative medicine applications.
- CEO / Founder
- Dae-jin Park
- Team Size
- 5 employees
- Stage
- Active
- Total Funding
- $4.5M
- Latest Round
- Accelerator
- Key Investors
- Korea Investment Partners; Daily Venture Capital; Company K Partners; Smilegate Investment; UTC Investment
Technology & Products
Key Products
Gel4Cell® (Bioink series); INNO GEL; Peptide-conjugated hydrogels; Human-derived collagen/ECM bioinks
Technological Advantage
First Korean developer of bioinks combining human-derived collagen and extracellular matrix (ECM) with hydrogels, optimizing the microenvironment for cell proliferation and differentiation in artificial organ production.
Differentiation
Value Proposition
Enables the production of artificial organs and tissues using human-derived collagen and ECM-based bioinks, representing the first such capability in the Korean market.
How They Differentiate
Differentiates through the use of human-derived materials rather than synthetic or animal-based alternatives, providing higher biocompatibility and more accurate physiological modeling for artificial organ development and drug testing.
Market & Competition
Target Customers
Research Universities; Regenerative Medicine Companies; Pharmaceutical R&D Centers; Hospitals
Industry Verticals
Medical; Regenerative Medicine
Competitors
T&R Biofab; Rokit Healthcare; Cellink (BICO)
Growth & Milestones
Growth Metrics
Raised $4.5M (5B KRW) Series A in 2021; Developed Korea's first human-derived collagen bioink; Established a dedicated GMP-certified production facility for medical-grade bioinks
Major Milestones
Developed high-functionality bioink for regenerative medicine; Established global sales partnership with German bio-instrument company GeSiM
Notable Customers
POSTECH (Pohang University of Science and Technology); Seoul National University Hospital; Kyungpook National University